Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01039155 · ClinicalTrials.gov registry record · Phase 1

Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy

A Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Adult Solid Neoplasm, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 1
Development phase
41
Enrollment target
1
Study location

NCT01039155 is a Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Adult Solid Neoplasm that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 41 participants, below the 953-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01039155, a Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Adult Solid Neoplasm, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 1
Development phase
41 participants
Enrollment target
1
Study location

Study Summary

This phase I clinical trial studies the side effects and the best dose of azacitidine and oxaliplatin in treating patients with advanced cancers that do not respond to treatment or have returned after any platinum therapy. Azacitidine is designed to activate (turn on) certain genes in cancer cells whose job is to fight tumors. Oxaliplatin is designed to block the growth and spread of new cancer cells, eventually destroying them, by damaging their deoxyribonucleic acid (DNA). Giving azacitidine with oxaliplatin may kill more cancer cells and may also reverse resistance to platinum-based drugs.

Conditions Studied

Hematopoietic and Lymphoid Cell Neoplasm Adult Solid Neoplasm

Interventions

  • DRUG Oxaliplatin
  • DRUG Azacitidine
  • OTHER Laboratory Biomarker Analysis
  • OTHER Pharmacological Study

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2009-12
Est. Completion 2015-07
Phase Phase 1

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01039155

The ClinicalTrials.gov registry entry for NCT01039155 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 953-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (96% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hematopoietic and Lymphoid Cell Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Oxaliplatin is the first listed.

NCT01039155 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT01039155 about?

NCT01039155 is a clinical study titled "Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy". This phase I clinical trial studies the side effects and the best dose of azacitidine and oxaliplatin in treating patients with advanced cancers that do not respond to treatment or have returned after any platinum therapy. Azacitidine is designed to activate (turn on) certain genes in cancer cells w...

What is the current status of trial NCT01039155?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2009-12. Estimated completion is 2015-07.

What conditions does trial NCT01039155 study?

This clinical trial studies the following conditions: Hematopoietic and Lymphoid Cell Neoplasm, Adult Solid Neoplasm.

What interventions are being tested in trial NCT01039155?

The interventions under investigation include: Oxaliplatin (DRUG), Azacitidine (DRUG), Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER).

Who is sponsoring clinical trial NCT01039155?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01039155 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hematopoietic and Lymphoid Cell Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hematopoietic and Lymphoid Cell Neoplasm

All registered trials for this condition

Adult Solid Neoplasm

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.